Login to Your Account



Achillion shares rise on interim win for short-course HCV regimen

By Michael Fitzhugh
Staff Writer

Monday, February 9, 2015

Updated interim phase II data showing that a combination of Achillion Pharmaceuticals Inc.'s NS5A inhibitor, ACH-3102, and Sovaldi (sofosbuvir, Gilead Sciences Inc.) cleared hepatitis C virus (HCV) in 100 percent of 12 genotype 1 patients after just six weeks of treatment pushed shares up 7.8 percent to $11.66 on Monday.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription